NEW YORK (GenomeWeb News) - ExonHit said yesterday that it has developed a prototype for a blood-based diagnostic to identify patients suffering from Alzheimer’s disease.
The company said the test is based on hybridizing RNA isolated from blood on an Affymetrix microarray, and it can distinguish patients suffering from Alzheimer’s disease from those suffering from schizophrenia, bipolar disorders, and depression.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.